Iimpawu, izizathu, kunye neZonyango kwi-Mixed Cellularity Classic Hodgkin Disease
Uhlobo olunjani oluxubekileyo lweHodgkin lymphoma, lufana kangakanani na, luyintoni ebangela ukuba lube nalo, kwaye luphathwa njani?
Sibanzi
I-cellularity i-Hodgkin's lymphoma uhlobo lwesifo se- Hodgkin , umhlaza weselimzimba. Luhlobo lwesibini oluqhelekileyo lwesifo se -Hodgkin , kunye nama-15 ukuya kuma-30 ekhulwini kubo bonke abantu ababhekene neHodgkin lymphoma ehlabathini lasentshona.
Inani lezigulane ezinolu hlobo lweHodgkin liphezulu kwiindawo zehlabathi ngaphandle kwe-United States, kuquka ne-Asia. Kwezinye iindawo, luhlobo oluqhelekileyo lweHodgkin lymphoma.
Iimpawu
I-cellularity i-Hodgkin inokubakho nawuphi na iminyaka, nangona ixhaphake kakhulu kubantu abadala phakathi kweminyaka engama-55 no-74, kunye nabantwana abangaphantsi kweminyaka eyi-14. Isantya sale hlobo lymphoma sibonakala sinciphile kwiziganeko phakathi kuka-1992 no-2011, kodwa oku kungakho ngenxa yeendlela i-lymphomas ezihlelwe ngayo endaweni yokunyuka kwenene kweziganeko.
Kuqheleke kakhulu kubantu abanamasosha omzimba asebenza kakubi, umzekelo, kubantu abane-HIV.
Izizathu
Ayaziwa oko kubangela isifo seHodgkin , nangona kukho izinto ezinobungozi eziye zafunyanwa. Ngohlobo oluxubekileyo lwe-lymphoma kukho iziganeko eziphezulu ze-Epstein-Barr ezikhoyo kwiiseli zomhlaza, kodwa izazinzulu zisengenakuqinisekiswa kobudlelwane obufanayo phakathi kwe-lymphomas kunye nale ntsholongwane obangela i-mononucleosis echaphazelayo.
Iimpawu
Iimpawu eziphambili zezifo ezixubekileyo zesistim zandisa i-lymph nodes entanyeni, izibilini kunye nesisu.
Ezinye izitho zingenakwenzeka ukuba zibandakanyeke nale fomu ye-lymphoma kunezinye iindidi ze-lymphoma. Izifo ezixubekileyo zesifo seepesenti ezingama-30 zabantu zibandakanyeka i-spleen yazo, iipesenti ezili-10 zabo zentsiba yomnatha, ama-3 ekhulwini kwesibindi, kunye ne-1 ukuya kwe-3 ekhulwini labantu ababandakanyeka kwezinye izitho.
Ukuxilongwa
Ukuxilongwa kwe-lymphoma kwenziwa nge- lymph node biopsy .
Unyango
Abantu abaninzi abaneli lymphoma bafumana ukuba banezifo eziphambili, ezibandakanya i-lymph nodes zombini kwindawo ephezulu yomzimba kunye nasesisu.
Kubantu abanesifo sokuqala , unyango lubandakanya ukudibanisa i-chemotherapy kunye neyeza zonyango.
Ngezifo eziphambili , iziganeko zonyango zihlala ziquka i-chemotherapy edeleyo, kwaye azinako ukubandakanya ukusetyenziswa kweyeza zonyango. Iinkqubo ze-Chemotherapy zixutyushwa kule nqaku malunga nokunyangwa kwe-Hodgkin lymphoma .
Kulabo abanokuphindaphindiweyo kweselfowuni exubileyo iHodgkin lymphoma, okanye ukuba unyango lokuqala luyaphela, kukho iindlela ezininzi. Omnye usebenzise i-salvage chemotherapy (i-chemotherapy esetyenziselwa ukunciphisa umthamo we-tumor kodwa ingaphilisi umhlaza) elandelwa ngumthamo omkhulu we-dose chemotherapy kunye ne-autologous stem cell transplant. Ezinye iindlela zingabandakanya ukusetyenziswa kwe- antioclonal antibody Blincyto (brentuximab, ) i- immunotherapy kunye ne-inhibitor ye- check - in , isilungiso se-stem cell cell, okanye ityala leklinikhi.
Prognosis
Nangona i-cellularity i-Hodgkin lymphoma ngumhlaza obulalayo , ukuxela kwangaphambili kukuhle kakhulu . Kufana nokufana nabantu abanomdlavuza we- Hodgkin lymphoma , kwaye bangcono kunabantu abane-lymphocyte isifo seHodgkin.
Ukujamelana
Kungakhathaliseki ukuba ukuxhamla, kuthusa ukuba kuhlolwe ngumhlaza, ngaphezu koko, unyango lokubeka olu hlobo lwesifo seHodgkin ekuxoxweni lunokuba ngumngeni omkhulu kwaye luye lugxotha, kwaye sifunda ukuba ukuxinezeleka akuyiyo ingcamango efanelekileyo kubantu abanemitholampilo . Fumana kwiintsapho kunye nabahlobo. Cinga ukujoyina iqela leenkxaso kuluntu lwakho okanye kwi-intanethi. Uze ujonge ezi ngcebiso malunga nokujongana ne-lymphoma
Imithombo:
Ansell, S. Hodgkin Lymphoma: Ukuxilongwa kunye noTyango. IMayo Clinic Proceedings . 2015. 90 (11): 1574-83.
U-Bienemann, K., uBorkhardt, A., uKlapper, W., kunye no-Oschi. Isiganeko esiphezulu segciwane lesifo se-Epstein-Barr (EBV) -i-Hodgkin lymphoma ephakamileyo kunye ne-Hodgkin lymphoma-efana ne-B-cell lymphoproliferations kunye neprofayili ye-EBV latency 2 kubantwana abane-interleukin-2-inducible T-cells kinase deficiency. Ubomi bakhe . 2015. 67 (5): 607-16.
I-Cancer: Imigaqo kunye nokuSebenza kwe-Oncology 7th Edition. Abahleli: VT DeVita, S Hellman kunye ne-SA Rosenberg. Ipapashwe nguLippincott Williams noWilkins, ngo-2005.
Glaser, S., Clarke, C., Keegan, T., Tshintsha, E., no-D. Weisenburger. Iimpawu zexesha kwiiRhafu zeHodgkin Lymphoma i-Histologic Subtypes: Intsingiselo yinyaniso okanye i-Evolving Diagnostic Practice? I-Epidemiology ye-Cancer Biomarkers kunye nokukhusela . 2015. 24 (10): 1474-88.
National Cancer Institute. Ukuqwalaselwa, i-Epidemiology, kunye neNkqubo yokuPhumela kweZiphumo. I-cellularity classic Hodgkin lymphoma. Fi kelelwa ngo-02/11/16. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5342/